Skip Ribbon Commands
Skip to main content

Persons with active, moderate to severe ulcerative colitis needed (MERIT-UC)

Trial Focus

Trial Focus



This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.

IRB Protocol #


Trial Status

Accepting Participants


Katelyn Cowan at 303-724-7875 or


University of Colorado HospitalUniversity of Colorado Hospital

Eligibility and Other Participant Information

Inclusion Criteria
•Ages of 18-70
•Ulcerative colitis has been diagnosed by routine criteria
At least one of the following applies:
•Steroid dependent
•Failed 5-ASA (mesalamine) therapy, such as Asacol®
•Failed/lost response to infliximab (Remicade®)
•Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (Purinethol) therapy
Exclusion Criteria (partial)
•Existing pregnancy, lactation, or planned pregnancy (men and women)
This research study includes:
•Physical exams and blood draws
•Taking an investigational drug weekly for up to 48 weeks
•Recording ulcerative colitis symptoms in a diary
** Compensation is provided **